ICAM-1


Also found in: Acronyms, Wikipedia.

ICAM-1

ICAM1

A gene on chromosome 19p13.3-p13.2 that encodes a cell surface glycoprotein expressed on endothelial cells and cells of the immune system. It binds to integrins CD11a/CD18 or CD11b/CD18, and serves as a cell receptor for rhinoviruses.
References in periodicals archive ?
Fasting serum samples were stored at -80[degrees]C for the analyses of TNF-[alpha], adiponectin, ICAM-1, and VCAM-1.
These groups were compared in terms of their age, gender, BMI (body mass index), disease history, total leucocyte count, neutrophil and lymphocyte percentage, and serum circulating levels of ICAM-1.
In the study, enzyme-linked immunosorbent assay (ELISA) was applied to determine the levels of serum inflammatory factors ICAM-1, YKL-40, and Lp-PLA2 in CHD patients.
Serum IL-1, IL-2, IL-6, IL-7, IL-8, and IL-18, ICAM-1, VCAM-1, CRP, TNF-[alpha], and P-selectin were evaluated using the Cusabio (Hubei Province, China) ELISA kits.
Notably, there were no significant differences in the expression of CD14, CD16, ICAM-1, HLA-DR, and CCR2 on any subset when cells from the same patient were compared before (at admission) and after clinical treatment (at remission).
We analyzed 13 markers which could be associated with preterm delivery IGFBP-1, IGFBP-2, BDNF, L-Selectin, E-Selectin, ICAM-1, PECAM, VCAM-1, MIP-1d, MIP-3b, Eotaxin-1, Eotaxin-2, and BLC, and we estimated their usefulness as markers for differentiation between threatened preterm delivery, preterm delivery, and false preterm delivery.
CerbB2 was negative in the cases with negative ICAM-1 whereas estrogen receptor and progesterone receptor were positive in the cases with positive VCAM-1.
Synthesis and secretion of ICAM-1 can be induced by interleukin-1 (IL-1) and tumor necrosis factor-[alpha] (TNF-[alpha]), and it functions as a ligand for lyphocyte function associated antigen 1 (LFA-1) (integrin) receptor found on leukocytes.
Figure 4 shows the temporal profiles of the amounts of VEGF, IL-6, ICAM-1, and MCP-1 in the vitreous body.
Subsequently, the tissue sections were incubated with the specific anti-human CD133 (1: 50; Biorbyt Ltd., #orb18124) or ICAM-1 (1: 100, G-5; Santa Cruz Biotechnology; sc-8439, Lot #F2111) antibody at room temperature for 1 hour under humid conditions.
CIHH treatment increased the expression of VLA-4, VCAM-1, and ICAM-1 in BMMSCs of AA rats but decreased the expression of CD162 and CD164.
The parallel rise of ICAM-1, observed in the present study, goes along with previous findings obtained in the SHRSP, where a decrease of this inflammatory and endothelial integrity marker represented a substantial achievement of strategies aimed to combat stroke [21-23].